Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Foundation for a Smoke Free World | Rose Research Center | Segal Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of EMB-001 as a Potential Smoking Cessation Treatment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Foundation for a Smoke Free World | Rose Research Center | Segal Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metyrapone,Oxazepam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The randomized, double-blind, placebo-controlled Phase 2 clinical trial is supported by funding from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health and will evaluate EMB-001 as a treatment option for patients with cocain...
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Metyrapone,Oxazepam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
January 19, 2018
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 05, 2016
Lead Product(s) : EMB-001
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metyrapone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
April 02, 2015
Lead Product(s) : Metyrapone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable